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Abstract The action exerted on non-L-, non-N-type (Q-like) 
Ca*+ channels by inununoglobulins G (IgGs) obtained from two 
patients with Lambert-Eaton myasthenic syndrome (LEMS) was 
investigated in the rat hrsullnoma RINmSF cell line. LEMS IgGs 
reduced by 3046% the whole-cell Ba*+ currents through Q-like 
Ca*+ channels at +lO mV without significantly modifying their 
voltage dependence and activation kinetics. Single- and multlple- 
channel recordings in cell-attached and outside-out patches of 
cells treated with LEMS IgGs showed no significant changes of 
the channel elementary properties but rather a decreased number 
of active channels per patch. This suggests that Q-like current 
depression by LEMS autoantibodies is mostly due to a down- 
regulation of functioning Ca*+ channels. In agreement with 
previous observations, LEMS IgGs also reduced by 20-33% the 
dihydropyridine-sensitive (L-type) Ba*+ current. The suggested 
down-regulation of Q-like channels by LEMS IgGs in RINm5F 
cells may have a functional correlation with the depressive action 
of LEMS autoantibodies on the P/Q-type Ca*+ channels 
controlling acetylcholine release from mammalian neuromuscu- 
lar junctions. 
Key words: Ca 2+ channel; Lambert-Eaton myasthenic 
syndrome; IgG; Insulinoma; RINmSF cell 
1. Introduction 
Lambert-Eaton myasthenic syndrome (LEMS) is a para- 
neoplastic autoimmune disease, often associated to small cell 
lung carcinoma (SCLC), which is characterized by a wide- 
spread impairment of neurotransmitter release from nerve 
terminals [1,2]. Motor disturbances occurring in LEMS pa- 
tients, such as muscle weakness and stretch reflex depression, 
have been attributed to a down-regulating action of LEMS 
autoantibodies on presynaptic Ca2+ channels causing a de- 
crease in acetylcholine (ACh) release at the neuromuscular 
junction [3]. Thus, there is great interest in identifying the 
voltage-dependent Ca ‘+ channels targeted by LEMS IgGs as 
well as the mechanisms underlying the IgG-Ca2+ channel in- 
teraction. Early electrophysiological studies pointed to an in- 
hibitory action of LEMS IgGs on L-type Ca2+ channels [4,5]. 
It has been shown, however, that L-type, as well as N-type 
channels, contribute marginally to the neurotransmitter re- 
lease from motoneuron terminals of mammals [6,7]. ACh re- 
lease in mammalian neuromuscular junctions is mainly con- 
trolled by a non-L-, non-N-type channel sensitive to o- 
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agatoxin IVA [8] and funnel-web spider toxin [9], i.e. by a 
P/Q-type channel [lo]. Recent studies on different cellular 
preparations have also shown that LEMS IgGs exert an in- 
hibitory action on several Ca2+ channel subtypes, including 
L-, N-, T-, and P-type [I l-131. While the action on N-type 
channels may account for the LEMS symptoms related to the 
altered catecholamine release from autonomic neurons [12,14], 
an effect on P/Q-type channels may be responsible for the 
motor function impairment in LEMS patients. 
The possibility that LEMS IgGs may down-regulate P/Q- 
type channels prompted us to test the effect of these autoan- 
tibodies on a newly described non-L-, non-N Ca2+ channel 
(‘Q-like’) expressed in rat insulinoma RINm5F cells [15]. The 
channel possesses biophysical and pharmacological properties 
similar to those described for the P/Q-type channels of per- 
ipheral and central neurons and contributes to a large propor- 
tion of Ca2+ currents in these cells [16]. Here we show that 
IgGs purified from sera of two LEMS patients reduce the 
non-L, non-N Ca2+ currents of RINm5F cells by 31-36% 
without affecting their voltage dependence, activation kinetics 
and single-channel properties. This action may be related to 
the down-regulation of presynaptic P/Q-type channels con- 
trolling ACh release in mammalian neuromuscular junctions 
which represent one of the main targets of LEMS autoanti- 
bodies. 
2. Materials and methods 
Rat insulinoma RINmSF cells were cultured as previously reported 
[ 16,171. Electrophysiological recordings were performed 46 days after 
plating. The standard internal solution was (mM): 110 CsCl, 10 
TEACl, 2 MgC12, 10 EGTA, 10 glucose, 10 HEPES (pH 7.3 with 
CsOH) and 0.1 uM TTX. 4 mM ATP and 0.2 mM CAMP were added 
to the internal standard solution to slow down the run-down of Ba’+ 
currents. The external recording solution was (mM): 120 NaCl, 10 
BaC&, 1 MgC12, 10 HEPES and 0.3 pM TTX to block Na+ currents 
(pH 7.3 with NaOH). Nifedipine (Bayer AG) was used at 5 nM final 
concentration from a 1 mM stock dissolved in ethanol (95%) and 
stored in the dark at 4°C. wCTX-GVIA was dissolved in distilled 
water and kept in stock aliquots at -20°C until usage at final con- 
centration of 3.2 PM. To maximize the irreversible blocking effect of 
o-CTx-GVIA, RINmSF cells were soaked for 15 min in standard 
Tyrode’s solution (2 mM [CaZ+]) containing the toxin. The perfusion 
system for solution exchange consisted of a multi-barrelled pipette 
connected to five syringes through teflon tubes (flow rate l-2 mYmin). 
Before electrophysiological recordings, the cells were incubated 
overnight in culture medium with IgGs (l-2 mg/ml) obtained from 
either healthy subjects (control) or LEMS patients (H and D). IgGs 
were purified from sera by ammonium sulfate precipitation, then dia- 
lysed against phosphate buffer saline, lyophilized and kept frozen in 
stock solutions (20 mg/ml) until use (see [2,14]). 
Electrophysiological recordings were performed with the patch- 
0014-5793/96/$12.00 0 1996 Federation of European Biochemical Societies. All rights reserved. 
PZZSOO14-5793(96)00465-6 
48 V. Magnelli et al.IFEBS Letters 387 (1996) 47-52 
A 
-90mV 
o-CTX-GVIA-treated 
Control IgG LEMS IgG (H) 
+lOmV 
1 CrR 
6 o-CTx-GVIA 
mV 
o-CTx-GVIA+Nife 
-40 0 +40 
0 
g -20 
B 
4 
2 -40 
$ 
Q-60 
e 
E 
= 0 -80 
-100 
non-L, non-N-type 
o LEMS IgGs (H) 
non-N-type 
Difference 
L-type 
Fig. 1. Inhibition of HVA Ca2+ channels induced by LEMS IgGs (H) in RINm5F cells pre-treated with 3.2 nM w-CTx-GVIA. After overnight 
incubation with either control or LEMS IgGs (2 mg/ml), the whole-cell Ba2+ currents were recorded before (C), during addition of 5 nM nife- 
dipine (Nife) and after wash-out (R). Current amplitudes were normalized to cell capacitance. A: Representative Ba2+ current traces recorded 
at +lO mV from -90 mV holding potential showing the marked reduction of current size induced by LEMS IgGs (H). The L-type component 
(lower traces), obtained by subtracting the Nife trace (2) from the C trace (l), is also reduced by LEMS IgGs. Note that the nifedipine block 
of control cells was completely reversible in 3045 s and was smaller than previously reported (25% vs. 55%, n = 30) [15,17], indicating a lower 
density of L-type channels expression in the RINm5F cells used for these experiments. B: I/V relationships of total (non-N-type), Q-like (non- 
L-, non-N-type) and DHP-sensitive (L-type) Ba2+ currents for control- (filled circles) and LEMS IgGs-treated cells (empty circles). Data points 
were collected from 8 cells treated with control IgGs and 8 cells treated with LEMS IgGs. Notice that average current amplitudes and percen- 
tage of LEMS IgGs inhibition differ from those derived from a larger number of cells (n = 28), due very likely to some variability of action of 
LEMS IgGs on different groups of cells. The I/V curves for the L-type channel were obtained by subtracting curve a and c and curve b and d, 
as indicated. Cells were pretreated with 3.2 pM w-CTx-GVIA and exposed to 5 uM nifedipine as detailed in panel A. 
clamp technique in whole-cell and cell-attached configurations [18] 
using the List EPC-7 amplifier (Darmstadt, Germany). Patch pipettes 
were pulled from borosilicate glass with a final tip resistance of 4-6 
MR for both configurations. For single channel experiments, elec- 
trode tips were coated with Sylgard 184 (Dow Corning Corp., Mid- 
land, MI, USA) to lower the pipette capacitance. Macroscopic cur- 
rents were acquired at lo-20 kHz (pClamp 5.0; Axon Instruments) 
and filtered at 5 kHz with an 8-pole low-pass filter. Single-channel 
recordings were sampled at 5-10 kHz and filtered at 2 kHz. The 
stimulation protocol consisted of voltage steps from -90 mV holding 
potential to voltages ranging from -40 to +50 mV. Most of the data 
refer to +lO mV test pulses. In whole-cell experiments, capacitive 
transient and leakage current compensation was performed both on 
line by the clamp-amplifier settings and off line by either subtracting 
Cd’+-insensitive currents (200 pM Cd2+) or using the P/4 technique 
with hyperpolarizing pulses from -90 mV. Current densities (pA/pF) 
were calculated by dividing the current amplitude by the CsioW setting 
required to minimize the cell capacity transient. To improve the clamp 
response, the electrode series resistance was compensated by 30-45%. 
In cell-attached and outside-out patch recordings, capacitive and leak 
currents were corrected by subtracting an average of ‘null’ sweeps. 
Data analysis was done using AutesP software (Garching Innovation, 
Munich, Germany) [16]. Data are expressed as mean? S.E.M. for 
n = number of cells. Student’s t-test was used for statistical evaluation. 
3. Results 
Of the three high-voltage-activated (HVA) Ca2+-channel 
subtypes identified in RINmSF cells (N-, L-type and Q-like) 
[15], the N-type contributes only a minor proportion of total 
Ba2+ currents (lO_15%) [17,19]. Its presence complicated the 
separation of the two other HVA channel currents; therefore, 
all the effects of LEMS IgGs described here were tested on 
RINmSF cells pre-treated with 3.2 p,M o-CTx-GVIA (15 min 
in 2 mM Ca2+) which abolished N-type channel activity. 
We first studied the effects of 2 mg/ml control and LEMS 
IgGs from patient H (IgGs (H)) on the total Ba2+ currents in 
o-CTx-GVIA-treated cells (Fig. 1A). Ba2+ current amplitude 
at + 10 mV in cells treated with control IgGs (45.4 + 4.1 pA/ 
pF, n=28) was significantly larger than that of cells treated 
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Fig. 2. Effects of control and LEMS IgGs on non-N, non-L type Ca *+ channels in RINmSF cells chronically treated with 3.2 uM o_CTx- 
GVIA and 5 uM nifedipine. A: Whole-cell Ba2+ currents recorded at potentials from -40 to +40 mV with step increments of 10 mV in cells 
treated with either control IgGs (top traces) or LEMS IgGs (bottom traces). B: Time-to-peak (tpeak) vs. voltage for non-L-, non-N-type Bazf 
currents recorded in control- (dots, n = 8) and LEMS IgGs (H)-treated cells (squares, n = 5). C: Comparison of the inhibitory effects induced by 
IgGs purified from sera of two different LEMS patients (H and D). Current amplitudes measured at +lO mV show comparable reductions 
(36.2% for patient H, n = 28, P < 0.01 and 30.7% for patient D, n = 18, PC 0.05). 
with LEMS IgGs (31.1 f 3.6 pA/pF, n=29), indicating a 32% 
current decrease by LEMS autoantibodies (P < 0.02). In order 
to evaluate the inhibitory effects of LEMS IgGs (H) on L-type 
and Q-like channels separately we then measured the size of 
the current remaining during addition of 5 pM nifedipine (Q- 
like) and the size of the current blocked by the DHP (L-type) 
in cells treated with LEMS and control IgGs. The residual Q- 
like current recorded at +lO mV decreased from 35.2f 3.6 
pA/pF (n=28) in control IgGs to 22.5 f2.6 pA/pF (n=28) 
in LEMS IgGs (H)-treated cells, indicating a current reduc- 
tion of 36.2% (P < 0.01). L-type currents were also depressed, 
but significantly less. The mean block of L-type currents was 
20.5% (n = 25). The stronger action of LEMS IgGs on Q-like 
channels than L-type channels was evident on a wide range of 
membrane potentials (-40 to +40 mV, Fig. 1B). The IN 
curves from 8 cells with significantly larger control currents 
(67.1 ? 13.0 pA/pF at +lO mV) were compared to those of 8 
other cells treated with LEMS IgGs (H). Q-like channels were 
inhibited by 40% at -20 mV and by 68% at +20 mV (middle 
panel in Fig. 1B) while the decrease of L-type channels was 
significantly lower: 23% at -20 mV and 18% at +20 mV 
(right panel). The stronger inhibition of non-L-, non-N-type 
channels by LEMS IgGs at positive potentials was unexpected 
and could be due to the existence of non-L-, non-N-type 
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Fig. 3. The kinetic parameters of single non-N-, non-L-type channel are not significantly modified by LEMS IgGs. Unitary Ba’+ currents were 
recorded in cell-attached patches of RINmSF cells chronically treated with ~&TX-GVIA and nifedipine after incubation with either control 
IgGs (A) or LEMS IgGs (B). Upper diagrams are open time distributions at +lO mV. The curves are single exponential functions with 7, 0.39 
ms (A) and 0.42 ms (B). Lower diagrams are closed time distributions at +lO mV fitted with double exponential functions with rcl 1.6 ms, rcz 
9.6 ms (A) and rcl 1.6, z,s 11 ms (B). C: Unitary current amplitude versus voltage for control- (dots) and LEMS IgGs-treated cells (squares). 
Same conditions as panels A and B. The regression lines through data points have a slope conductance of 19.2 and 20.0 pS, respectively. D: 
Ensemble Ba2+ currents obtained by adding 45 sweeps from 19 outside-out patches of either control- (top trace) or LEMS IgGs-treated cells 
(bottom trace) containing multiple non-N-, non-L-type channels. 
channel subpopulations with different sensitivity to LEMS 
IgGs: one more sensitive and activating at more positive po- 
tentials and one resistant to LEMS IgGs activating at slightly 
more negative potentials. This point was not further investi- 
gated in this study. Notice, however, that the percentage of 
inhibition of Q-like channels derived from Fig. 1B (63.3% at 
+lO mV, n = 8 cells) is much larger than that derived from 28 
cells at the same potential (36.2%), suggesting a variability of 
LEMS IgGs action among groups of cells. 
LEMS IgGs (H) had little effect on the activation-inactiva- 
tion kinetics of Q-like channels. The voltage dependence and 
absolute values of the time-to-peak (tpeak) at potentials be- 
tween -30 and +30 mV did not significantly differ in control 
and LEMS IgG-treated cells (Fig. 2A). In both groups of 
cells, tpeak decreased in a sharply voltage-dependent manner 
from 2.8 ms at -30 mV to 0.3 ms at +30 mV. At +lO mV, 
tpeak was 0.54 f 0.09 ms in control IgG- and 0.66 f 0.08 ms in 
LEMS IgG-treated cells. Similar effects were observed while 
testing the action of LEMS IgGs of a second patient (D). Q- 
like currents at +lO mV were significantly reduced by LEMS 
IgGs (D) but by a minor percentage in comparison to the 
IgGs of patient H (30.7% vs. 36.2%, Fig. 2C). LEMS IgGs 
(D) also reduced Ba2+ currents through L-type channels by 
33.1%, i.e. by a larger degree than LEMS IgGs (H) (20.5% 
reduction) but by a percentage comparable to that induced by 
the same autoantibodies on the L-type channel of human 
neuroblastoma IMR32 cells (30.0% reduction [12]). 
To verify whether LEMS IgGs affected either the number 
or the elementary properties of functioning channels, the ac- 
tivity of Q-like channels was studied in cell-attached and out- 
side-out patches. Cells were pre-treated with w-CTx-GVIA 
and exposed to saturating doses of nifedipine. Single Q-like 
channel activity recorded in cell-attached patches of cells trea- 
ted either with control IgGs (Fig. 3A) or with LEMS IgGs(H) 
(Fig. 3B) showed strong similarities. In both cellular popula- 
tions, non-L-, non-N-type channels started to activate positive 
to 0 mV from -90 mV holding potential. The channel open 
probability &) at +lO mV was not significantly different 
(9.9? 1.2% in control cells and 12Sf 1.6% in LEMS IgGs 
(H), P < 0.05) and the same was true for the single channel 
conductance (y) estimated between -20 and +20 mV. y was 
19.2 pS in control patches and 20 pS in LEMS IgGs (H)- 
treated patches (Fig. 3C). The open time histogram distribu- 
tion at +lO mV was fitted by a single exponential function 
with a mean open time (zO) of 0.39 and 0.42 ms while the 
closed time histogram distribution was fitted by two exponen- 
tials with corresponding values: 1.6 and 9.6 ms for cells treat- 
ed with control IgGs and 1.6 and 11 ms for LEMS IgGs (H)- 
treated cells. These results suggest that LEMS IgGs do not 
interfere with channel p. but rather down-regulate the number 
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of functioning channels. Direct evidence for this comes from 
the observation that the probability of finding active channels 
in LEMS IgGs (H)-treated patches was significantly smaller 
compared to control IgGs-treated patches (only in 14 out of 
31 patches). On the average, control patches always contained 
a higher number of active channels than LEMS IgGs (H)- 
treated patches. This was particularly evident in outside-out 
patches that usually contained multiple channels. In 16 out of 
17 control outside-out patches we could observe an average 
activity of more than 3 channels, while in LEMS IgGs (H)- 
treated patches channel activity was limited to 1 or 2 channels 
and detected only in 9 out of 17 patches. The reconstituted 
currents obtained by averaging 45 sweeps from an equal num- 
ber of control and LEMS IgGs (H)-treated patches had mark- 
edly different size but similar activation-inactivation kinetics 
(Fig. 3D). The averaged currents in LEMS IgGs (H)-treated 
cells were 57% smaller than control patches, indicating a re- 
duction in the number of active channels probably due to a 
down-regulation of Q-like channels as already reported for 
other Ca2+ channels [4,12]. 
4. Discussion 
The presence of a significant fraction of non-L, non-N-type 
Ca2+ channels in RINm5F cells, with biophysical and phar- 
macological properties close to the Q-type channel, makes this 
cell line a suitable model to investigate the inhibitory action of 
LEMS IgGs on the P/Q-type channels controlling the presy- 
naptic Ca*+ entry in mammalian neuromuscular junctions [9]. 
ACh release in motor nerve terminals is insensitive to N- and 
L-type channel blockers [6,7] while it is reversibly abolished 
by nanomolar concentrations of o-Aga-IVA and by lo*-fold 
higher concentrations of w-CTx-MVIIC [S]. Thus, the phar- 
macological profile of the non-L, non-N-type channel control- 
ling neurotransmitter release in mammalian motoneurons is 
close, although not identical, to the P-type channel of central 
neurons [lo]. The P-type channel of cerebellar Purkinje neu- 
rons is irreversibly blocked by nanomolar concentrations of 
o-Aga-IVA and micromolar amounts of o-CTx-MVIIC [20]. 
In this respect, the non-N, non-L-type channel of RINmSF 
cells resembles more the P-type channel of motoneuron termi- 
nals than that of central neurons: it is reversibly blocked by 
nanomolar concentrations of o-Aga-IVA and irreversibly 
abolished by micromolar concentrations of o-CTx-MVIIC 
[15]. Channels containing class A al subunits may form a 
broad family of non-L-, non-N type Ca2+ channels with dif- 
ferent sensitivity to w-Aga-IVA and o-CTx-MVIIC but close 
structural and biophysical properties. The effects observed on 
non-L, non-N-type channels of RINmSF cells may be sugges- 
tive of LEMS IgGs action on similar class A Ca2+ channels 
expressed in motoneuron terminals. 
Our data show that LEMS IgGs inhibit the Ba2+ currents 
through the non-L, non-N-type channels of RINmSF cells by 
down-regulating the number of functioning channels. Macro- 
scopic Ba2+ currents were reduced by 31l36% with no 
changes of their activation kinetics and single channel current 
properties. The finding that LEMS IgGs down-regulate P/Q- 
type channels is in agreement with results of immunoprecipi- 
tation studies showing the presence of anti-P/Q-type Ca2+ 
channel autoantibodies in sera of 62 out of 65 LEMS patients 
[21,22] and with a voltage-clamp study showing that LEMS 
IgG reduces the P-type channel current in SCLC cells [13]. 
These cells had been previously shown to express mRNA for 
P-type Ca 2+ channels [23,24] and to possess a Ca2+ conduc- 
tance insensitive to DHPs and w-CTx-GVIA but depressed by 
nanomolar concentrations of o-Aga-IVA [24]. The experimen- 
tal evidence that SCLC cells express non-L-, non-N-type 
channels, the presence of IgGs against these channels in 
most LEMS sera and the finding that class A channels control 
ACh release from mammalian motoneurons, suggest that the 
marked down-regulation of non-L-, non-N-type channels by 
LEMS IgGs reported here may be functionally correlated to 
the impairment of motor function observed in LEMS patients. 
We have recently shown that LEMS IgGs also down-reg- 
ulate N-, L- and T-type Ca 2+ channels in human neuroblas- 
toma IMR32 cells, reducing the corresponding Ba2+ currents 
up to 55%, 49% and 48%, respectively [12]. These data, to- 
gether with the present finding of an inhibitory action on Q- 
like Ca2+ channels and the depression of Na+ currents re- 
ported in SCLC cells [25], suggest that LEMS IgGs exert a 
broad action on different voltage-dependent channels. The 
question then arises if there exists any specificity in LEMS 
IgGs action and what might be the origin of its variability 
on the different Ca2+ channel subtypes. A possible explana- 
tion for the broad action of LEMS IgGs is that different 
channels may share common antigenic sites to which the auto- 
antibodies are directed. Ca2+ and Na+ channel o1 subunits in 
fact possess regions of considerable amino acid sequence 
homology [26] which may result in some structural and anti- 
genie similarities among these channels [21]. On the other 
hand, SCLC cells, which are considered responsible for the 
autoimmune response in LEMS patients, express a variety of 
Ca2+ channels: L-, N- and P/Q-types [23,24] as well as Na+ 
and K+ channels [27]. It seems reasonable, therefore, that 
each one of these channel proteins may represent an inde- 
pendent antigenic stimulus for the production of specific auto- 
antibodies. A different immune response occurring in each 
patient might then account for the variable proportions of 
Ca2+ channel subtypes targeted by LEMS autoantibodies. 
This might also explain the large variability in the severity 
of the disease as well as the degree of neurological complica- 
tions observed in these patients. The inhibitory action exerted 
by LEMS IgGs on N-type [12,14] and P-type channels ([13,21] 
and present data) may account for the impairment of neuro- 
transmitter release from autonomic and motoneuron termi- 
nals, respectively, thus explaining the most frequently ob- 
served symptoms in LEMS patients. Whether inhibition on 
L- and T-type channels has any correlation with the patho- 
genesis of LEMS symptoms remains still to be elucidated. 
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